Vaxcyte has signed a new agreement with Lonza to manufacture pneumococcal conjugate vaccines. Credit: Mufid Majnun on Unsplash.

Vaxcyte has signed a new commercial agreement with Lonza for the global manufacture of broad-spectrum pneumococcal conjugate vaccines (PCVs).

Building on an existing collaboration, the new deal will enable the commercialisation of Vaxcyte’s PCV candidates, VAX-24 and VAX-31, for both paediatric and adult populations globally.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This agreement supports Vaxcyte’s strategy to leverage Lonza’s existing infrastructure for clinical development and the upcoming US launch of VAX-24 for adults.

Lonza will offer Vaxcyte a custom-built manufacturing suite as part of its Ibex Dedicate Biopark at its site in Visp, Switzerland.

The suite will be used to produce essential components for Vaxcyte’s PCV franchise.

Starting with VAX-24, which is advancing towards late-stage clinical trials, Vaxcyte’s manufacturing facility will help address the long-term global market needs for both adults and children.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The manufacturing suite’s design is almost finished and equipment installation is set to commence in 2024.

Lonza will create 300 new jobs at peak production.

Lonza biologics president Jean-Christophe Hyvert stated: “Having supported the early-stage clinical development of Vaxcyte’s PCV programmes, we are pleased to continue our long-standing collaboration by supporting the late-stage clinical manufacturing utilising our unique IbexDedicate offering, with the capability to provide commercial supply of their products.”

In 2022 to 2023, Vaxcyte achieved significant advancements in its VAX-24 clinical programme, including two positive Phase II results in adults and the commencement of a Phase II study in infants.

Vaxcyte CEO and co-founder Grant Pickering stated: “Following the successful completion of our VAX-24 Phase II adult studies, and as we prepare for Phase III clinical studies, we are excited to expand our relationship with Lonza, a pre-eminent contract development and manufacturing organisation, and put into motion the key steps required to establish large-scale and long-term commercial manufacturing capacity for our PCV candidates.”